LCLA.F PT Kalbe Farma Tbk

Healthcare Metals & Mining Frankfurt Exchange
0.0295 EUR
Close of Nov 12, 2026
0.0235 0.0656
Market cap
EUR 1.33B
P/E
-
P/B
1.13x
ROE
14.5%
Dividend yield
3.38%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LCLA.F undervalued?

Graham number

The Graham number of PT Kalbe Farma Tbk cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PT Kalbe Farma Tbk fundamental analysis

No fundamental analysis for PT Kalbe Farma Tbk yet.

PT Kalbe Farma Tbk stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PT Kalbe Farma Tbk

PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products. In…

Full company profile